<DOC>
	<DOCNO>NCT02209324</DOCNO>
	<brief_summary>A multicenter , open-label study conduct evaluate efficacy safety ASP2151 patient herpes simplex ( recurrent labial/facial herpes recurrent genital herpes Kaposi varicelliform ) .</brief_summary>
	<brief_title>Open-label Study ASP2151 Herpes Simplex Patients</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>1 . Patients rash associate herpes simplex recurrent episode meeting follow criterion Recurrent labial/facial herpes : Patients least 10 papulae vesicles/pustules Recurrent genital herpes : Patients least 5 papule vesicles/pustules genital organ genital circumanal region Kaposi varicelliform eruption : Patients major skin symptom papulae vesicle 2 . Patients start receive study drug within 48 hour onset rash 3 . Age : 16 year old , young 80 year 1 . Patients expect adequate response oral antiviral medication . 2 . Patients two type herpes simplex . 3 . An extreme decline immune function 4 . Presence serious complication 5 . Patients find meet follow condition base laboratory test perform within 14 day inform consent : AST ALT ≥ 2.5 x upper limit normal Platelet count &lt; low limit normal Serum creatinine ≥ 1.5 mg/dL Creatinine clearance &lt; 30 mL/min 6 . Current previous history malignant tumor within 5 year inform consent 7 . Diagnosis autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>